A prototypical process for creating evidentiary standards for biomarkers and diagnostics.

Area of Science:

• Biomarker Development
• Regulatory Science
• Drug Discovery

Background:

• The Food and Drug Administration's Critical Path Initiative highlighted the need for robust biomarker qualification standards.
• Existing methods for establishing biomarker evidentiary standards lack a systematic, adaptable framework.

Purpose of the Study:

• To describe a systematic framework for developing evidentiary standards for biomarker qualification.
• To test and refine this framework through a collaborative workshop.

Main Methods:

• Development of a systematic framework by Pharmaceutical Research and Manufacturers of America (PhRMA) committees.
• Testing the framework in a workshop involving the Food and Drug Administration (FDA) and academic experts.
• Incorporating necessary refinements based on workshop feedback.

Main Results:

• The developed framework provides a structured approach to biomarker qualification.
• The workshop demonstrated the framework's applicability and identified areas for refinement.
• The framework is adaptable for various biomarker purposes.

Conclusions:

• The systematic framework offers a viable pathway for establishing biomarker evidentiary standards.
• Collaborative refinement is key to creating individualized and appropriate standards.
• This framework can support the advancement of the FDA's Critical Path Initiative for biomarker use.